Severe cutaneous adverse reactions associated with systemic antibiotics in acne vulgaris: a systematic review.

J Dermatolog TreatJun 30, 2026 (epub)
Clinical ResearchDermatology

Ivan Arni C Preclaro, Po-Chien Wu, Mary Caroline Go et al.

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

Acne vulgaris (AV) is an inflammatory disorder of the pilosebaceous unit commonly managed with systemic antibiotics. Since antibiotics are known triggers of severe cutaneous adverse drug reaction (SCARs), patients with AV receiving prolonged antibiotics are at potential risk.

Reported results

Twenty-eight articles (27 reports, 1 case series) were identified, encompassing a total of 31 patients with SCARs. Tetracycline class was the most frequently implicated antibiotic, with a mean latency period of approximately 4 weeks.

Authors' conclusions

Although rare, SCARs may occur in AV patients receiving systemic antibiotics. Clinicians should maintain a high index of suspicion during therapy, ensure regular follow-up, and counsel patients on early recognition of skin reactions to mitigate potential risks.

Source

PubMed · PMID 42377117

Published in J Dermatolog Treat. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.